232 related articles for article (PubMed ID: 28118809)
21. Mitochondrial Damage and Drp1 Overexpression in Rifampicin- and Isoniazid-induced Liver Injury Cell Model.
Li F; Zhou J; Li Y; Sun K; Chen J
J Clin Transl Hepatol; 2019 Mar; 7(1):40-45. PubMed ID: 30944818
[No Abstract] [Full Text] [Related]
22. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
23. Role of oxidative stress and nitric oxide in the protective effects of alpha-lipoic acid and aminoguanidine against isoniazid-rifampicin-induced hepatotoxicity in rats.
Saad EI; El-Gowilly SM; Sherhaa MO; Bistawroos AE
Food Chem Toxicol; 2010 Jul; 48(7):1869-75. PubMed ID: 20417245
[TBL] [Abstract][Full Text] [Related]
24. Monoammonium glycyrrhizinate protects rifampicin- and isoniazid-induced hepatotoxicity via regulating the expression of transporter Mrp2, Ntcp, and Oatp1a4 in liver.
Zhou L; Song Y; Zhao J; Qin H; Zhang G; Zhou Y; Wu X
Pharm Biol; 2016; 54(6):931-7. PubMed ID: 26987268
[TBL] [Abstract][Full Text] [Related]
25. Hepatocyte growth factor protects against isoniazid/rifampicin-induced oxidative liver damage.
Enriquez-Cortina C; Almonte-Becerril M; Clavijo-Cornejo D; Palestino-Domínguez M; Bello-Monroy O; Nuño N; López A; Bucio L; Souza V; Hernández-Pando R; Muñoz L; Gutiérrez-Ruiz MC; Gómez-Quiroz LE
Toxicol Sci; 2013 Sep; 135(1):26-36. PubMed ID: 23764483
[TBL] [Abstract][Full Text] [Related]
26. Serum biomarkers of isoniazid-induced liver injury: Aminotransferases are insufficient, and OPN, L-FABP and HMGB1 can be promising novel biomarkers.
Cheng X; Zhu JL; Li Y; Luo WW; Xiang HR; Zhang QZ; Peng WX
J Appl Toxicol; 2022 Mar; 42(3):516-528. PubMed ID: 34494278
[TBL] [Abstract][Full Text] [Related]
27. The protective effects of ursodeoxycholic acid on isoniazid plus rifampicin induced liver injury in mice.
Chen X; Xu J; Zhang C; Yu T; Wang H; Zhao M; Duan ZH; Zhang Y; Xu JM; Xu DX
Eur J Pharmacol; 2011 May; 659(1):53-60. PubMed ID: 21419764
[TBL] [Abstract][Full Text] [Related]
28. Kinetic Evaluation of Determinant Factors for Cellular Accumulation of Protoporphyrin IX Induced by External 5-Aminolevulinic Acid for Photodynamic Cancer Therapy.
Nakanishi T; Ogawa T; Yanagihara C; Tamai I
J Pharm Sci; 2015 Sep; 104(9):3092-100. PubMed ID: 25959076
[TBL] [Abstract][Full Text] [Related]
29. Lipid peroxidation aggravates anti-tuberculosis drug-induced liver injury: Evidence of ferroptosis induction.
Pan Y; Tang P; Cao J; Song Q; Zhu L; Ma S; Zhang J
Biochem Biophys Res Commun; 2020 Dec; 533(4):1512-1518. PubMed ID: 33121683
[TBL] [Abstract][Full Text] [Related]
30. Isoniazid and its toxic metabolite hydrazine induce in vitro pyrazinamide toxicity.
Tostmann A; Boeree MJ; Peters WH; Roelofs HM; Aarnoutse RE; van der Ven AJ; Dekhuijzen PN
Int J Antimicrob Agents; 2008 Jun; 31(6):577-80. PubMed ID: 18358703
[TBL] [Abstract][Full Text] [Related]
31. Rifampicin and isoniazid increase acetaminophen and isoniazid cytotoxicity in human HepG2 hepatoma cells.
Nicod L; Viollon C; Regnier A; Jacqueson A; Richert L
Hum Exp Toxicol; 1997 Jan; 16(1):28-34. PubMed ID: 9023573
[TBL] [Abstract][Full Text] [Related]
32. Reparation of Isoniazid and Rifampicin Combinatorial Therapy-Induced Hepatotoxic Effects by Bacopa monnieri.
Evan Prince S; Udhaya LB; Sunitha PS; Arumugam G
Pharmacology; 2016; 98(1-2):29-34. PubMed ID: 27007136
[TBL] [Abstract][Full Text] [Related]
33. Silencing of human ferrochelatase causes abundant protoporphyrin-IX accumulation in colon cancer.
Kemmner W; Wan K; Rüttinger S; Ebert B; Macdonald R; Klamm U; Moesta KT
FASEB J; 2008 Feb; 22(2):500-9. PubMed ID: 17875605
[TBL] [Abstract][Full Text] [Related]
34. Results of a pilot study of isoniazid in patients with erythropoietic protoporphyria.
Parker CJ; Desnick RJ; Bissel MD; Bloomer JR; Singal A; Gouya L; Puy H; Anderson KE; Balwani M; Phillips JD
Mol Genet Metab; 2019 Nov; 128(3):309-313. PubMed ID: 31395332
[TBL] [Abstract][Full Text] [Related]
35. Toxicoproteomic Profiling of
Brewer CT; Kodali K; Wu J; Shaw TI; Peng J; Chen T
Cells; 2020 Jul; 9(7):. PubMed ID: 32660103
[TBL] [Abstract][Full Text] [Related]
36. [Clinical study on the cases in which INH or RFP was discontinued during treatment for pulmonary tuberculosis].
Harada S; Takamoto M; Ishibashi T; Mohri M; Sato K; Yamagishi F; Sasaki Y; Tanabe K; Sato R; Fujino T; Tano M; Tanizawa M; Sakatani M; Morimoto T; Kawahara S; Hotta N; Shigeto E; Nishimura K; Abe T; Iwanaga T; Oe T; Shimazu K; Ebihara M; Nakagawa S; Kuba M;
Kekkaku; 2001 May; 76(5):427-36. PubMed ID: 11449698
[TBL] [Abstract][Full Text] [Related]
37. Hepatoprotective effect of tocopherol against isoniazid and rifampicin induced hepatotoxicity in albino rabbits.
Tayal V; Kalra BS; Agarwal S; Khurana N; Gupta U
Indian J Exp Biol; 2007 Dec; 45(12):1031-6. PubMed ID: 18254208
[TBL] [Abstract][Full Text] [Related]
38. [Attributable factors to the emergence of multidrug-resistant Mycobacterium tuberculosis based on the observation of consecutive drug resistance test results].
Fujino T; Hasegawa N; Satou R; Komatsu H; Kawada K
Kekkaku; 1998 Jul; 73(7):471-6. PubMed ID: 9739579
[TBL] [Abstract][Full Text] [Related]
39. Study of oxidative-stress in isoniazid-rifampicin induced hepatic injury in young rats.
Sodhi CP; Rana SV; Mehta SK; Vaiphei K; Attari S; Mehta S
Drug Chem Toxicol; 1997 Aug; 20(3):255-69. PubMed ID: 9292280
[TBL] [Abstract][Full Text] [Related]
40. [Desensitization therapy for allergic reactions of antituberculous drugs--evaluation of desensitization therapy according to the guideline of the Japanese Society for Tuberculosis].
Kobashi Y; Okimoto N; Matsushima T; Abe T; Nishimura K; Shishido S; Kawahara S; Shigeto E; Takeyama H; Kuraoka T
Kekkaku; 2000 Dec; 75(12):699-704. PubMed ID: 11201137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
